Michael R Zile1, JoAnn Lindenfeld2, Fred A Weaver3, Faiez Zannad4, Elizabeth Galle5, Tyson Rogers6, William T Abraham7. 1. Medical University of South Carolina, Charleston, South Carolina; Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, South Carolina. Electronic address: zilem@musc.edu. 2. Vanderbilt Heart and Vascular Institute, Nashville, Tennessee. 3. Division of Vascular Surgery and Endovascular Therapy, Keck School of Medicine, University of Southern California, Los Angeles, California. 4. Inserm Centre d'Investigation, CHU de Nancy, Institute Lorrain du Coeur et des Vaisseaux, Université de Lorraine, Nancy, France. 5. CVRx, Inc., Minneapolis, Minnesota. 6. NAMSA, Inc., Minneapolis, Minneapolis. 7. Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio.
Abstract
BACKGROUND: This study demonstrated the safety and effectiveness of baroreflex activation therapy (BAT) in patients with heart failure with reduced ejection fraction (HFrEF). OBJECTIVES: The BeAT-HF (Baroreflex Activation Therapyfor Heart Failure) trial was a multicenter, prospective, randomized, controlled trial; subjects were randomized 1:1 to receive either BAT plus optimal medical management (BAT group) or optimal medical management alone (control group). METHODS:Four patient cohorts were created from 408 randomized patients with HFrEF using the following enrollment criteria: current New York Heart Association (NYHA) functional class III or functional class II (patients who had a recent history of NYHA functional class III); ejection fraction ≤35%; stable medical management for ≥4 weeks; and no Class I indication for cardiac resynchronization therapy. Effectiveness endpoints were the change from baseline to 6 months in 6-min hall walk distance (6MHW), Minnesota Living with HF Questionnaire quality-of-life (QOL) score, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. The safety endpoint included the major adverse neurological or cardiovascular system or procedure-related event rate (MANCE). RESULTS: Results from, timeline and rationale for, cohorts A, B, and C are presented in detail in the text. Cohort D, which represented the intended use population that reflected the U.S. Food and Drug Administration-approved instructions for use (enrollment criteria plus NT-proBNP <1,600 pg/ml), consisted of 245 patients followed-up for 6 months (120 in the BAT group and 125 in the control group). BAT was safe and significantly improved QOL, 6MHW, and NT-proBNP. In the BAT group versus the control group, QOL score decreased (Δ = -14.1; 95% confidence interval [CI]: -19 to -9; p < 0.001), 6MHW distance increased (Δ = 60 m; 95% CI: 40 to 80 m; p < 0.001), NT-proBNP decreased (Δ = -25%; 95% CI: -38% to -9%; p = 0.004), and the MANCE free rate was 97% (95% CI: 93% to 100%; p < 0.001). CONCLUSIONS:BAT was safe and significantly improved QOL, exercise capacity, and NT-proBNP. (Baroreflex Activation Therapyfor Heart Failure [BeAT-HF]; NCT02627196).
RCT Entities:
BACKGROUND: This study demonstrated the safety and effectiveness of baroreflex activation therapy (BAT) in patients with heart failure with reduced ejection fraction (HFrEF). OBJECTIVES: The BeAT-HF (Baroreflex Activation Therapy for Heart Failure) trial was a multicenter, prospective, randomized, controlled trial; subjects were randomized 1:1 to receive either BAT plus optimal medical management (BAT group) or optimal medical management alone (control group). METHODS: Four patient cohorts were created from 408 randomized patients with HFrEF using the following enrollment criteria: current New York Heart Association (NYHA) functional class III or functional class II (patients who had a recent history of NYHA functional class III); ejection fraction ≤35%; stable medical management for ≥4 weeks; and no Class I indication for cardiac resynchronization therapy. Effectiveness endpoints were the change from baseline to 6 months in 6-min hall walk distance (6MHW), Minnesota Living with HF Questionnaire quality-of-life (QOL) score, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. The safety endpoint included the major adverse neurological or cardiovascular system or procedure-related event rate (MANCE). RESULTS: Results from, timeline and rationale for, cohorts A, B, and C are presented in detail in the text. Cohort D, which represented the intended use population that reflected the U.S. Food and Drug Administration-approved instructions for use (enrollment criteria plus NT-proBNP <1,600 pg/ml), consisted of 245 patients followed-up for 6 months (120 in the BAT group and 125 in the control group). BAT was safe and significantly improved QOL, 6MHW, and NT-proBNP. In the BAT group versus the control group, QOL score decreased (Δ = -14.1; 95% confidence interval [CI]: -19 to -9; p < 0.001), 6MHW distance increased (Δ = 60 m; 95% CI: 40 to 80 m; p < 0.001), NT-proBNP decreased (Δ = -25%; 95% CI: -38% to -9%; p = 0.004), and the MANCE free rate was 97% (95% CI: 93% to 100%; p < 0.001). CONCLUSIONS: BAT was safe and significantly improved QOL, exercise capacity, and NT-proBNP. (Baroreflex Activation Therapy for Heart Failure [BeAT-HF]; NCT02627196).
Authors: Tarun W Dasari; Tamas Csipo; Faris Amil; Agnes Lipecz; Gabor A Fulop; Yunqiu Jiang; Rajesh Samannan; Sarah Johnston; Yan D Zhao; Federico Silva-Palacios; Stavros Stavrakis; Andriy Yabluchanskiy; Sunny S Po Journal: J Card Fail Date: 2020-12-31 Impact factor: 6.592
Authors: Mona Fiuzat; Carine E Hamo; Javed Butler; William T Abraham; Ersilia M DeFilippis; Gregg C Fonarow; Joann Lindenfeld; Robert J Mentz; Mitchell A Psotka; Scott D Solomon; John R Teerlink; Muthiah Vaduganathan; Orly Vardeny; John J V McMurray; Christopher M O'Connor Journal: J Am Coll Cardiol Date: 2022-02-08 Impact factor: 27.203
Authors: Dragana Kosevic; Dominik Wiedemann; Petar Vukovic; Velibor Ristic; Julia Riebandt; Una Radak; Kersten Brandes; Peter Goettel; Hans-Dirk Duengen; Elvis Tahirovic; Tatjana Kottmann; Hans Werner Voss; Marija Zdravkovic; Svetozar Putnik; Jan D Schmitto; Johannes Mueller; Jesus Eduardo Rame; Miodrag Peric Journal: ESC Heart Fail Date: 2021-02-09
Authors: John Bisognano; John E Schneider; Shawn Davies; Robert L Ohsfeldt; Elizabeth Galle; Ivana Stojanovic; Thomas F Deering; JoAnn Lindenfeld; Michael R Zile Journal: BMC Cardiovasc Disord Date: 2021-03-26 Impact factor: 2.298
Authors: Shelby D Reed; Jui-Chen Yang; Timothy Rickert; F Reed Johnson; Juan Marcos Gonzalez; Robert J Mentz; Mitchell W Krucoff; Sreekanth Vemulapalli; Philip B Adamson; David J Gebben; Liliana Rincon-Gonzalez; Anindita Saha; Daniel Schaber; Kenneth M Stein; Michelle E Tarver; Dean Bruhn-Ding Journal: Circ Heart Fail Date: 2021-12-23 Impact factor: 8.790
Authors: Yusra Zaidi; Eslie G Aguilar; Miguel Troncoso; Daria V Ilatovskaya; Kristine Y DeLeon-Pennell Journal: Cell Signal Date: 2020-11-15 Impact factor: 4.850
Authors: Ana Jorbenadze; Marat Fudim; Felix Mahfoud; Phillip B Adamson; Tarek Bekfani; Rolf Wachter; Horst Sievert; Piotr P Ponikowski; John G F Cleland; Stefan D Anker Journal: ESC Heart Fail Date: 2021-05-18